Compare Moderna, Inc. (MRNA) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Procter & Gamble Co — how do they compare? Moderna, Inc. trades at $224.38 (market cap $78.65B), while Procter & Gamble Co trades at $151.21 (market cap $349.77B). The key difference: Procter & Gamble Co is far larger — about 4.4× Moderna, Inc.'s market cap, and Procter & Gamble Co pays a 2.89% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Procter & Gamble Co for 131 Days on average.
| MRNA | PG | |
|---|---|---|
Market Cap | $78.65B | $349.77B |
Volume | 37,373,437 | 10,055,825 |
Sector | Health | Consumer Staples |
52-Week High | $203.46 | $167.18 |
52-Week Low | $22.36 | $138.10 |
Typical Hold Time | 59 Days | 131 Days |
Enterprise Value | $74.80B | $375.61B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Procter & Gamble (PG) trades at $150.87, up 2.06% today, showing strong momentum near its consensus price target of $160.13. The stock maintains a bullish technical outlook with moving averages supporting upward momentum, while fundamentals reveal consistent earnings beats and robust profitability with 18.44% net margins. Recent corporate developments include a new WNBA partnership and a $1.09 dividend declaration, reinforcing its stable income appeal.
PG offers reliable growth with three consecutive earnings beats and strong cash flow generation, though premium valuation multiples pose near-term risk. The company's supply chain enhancements and dividend track record provide stability, but investors face headwinds from soft demand concerns and elevated P/E ratios. Wall Street maintains a bullish stance with 53% buy ratings, suggesting moderate upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
